Affimed NV (AFMD)

[TwoNE1]

study update: AFM13+pembro in HL completed, AFM11 in NHL terminated

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Status : Completed
First Posted : January 28, 2016
Last Update Posted : May 16, 2019

https://clinicaltrials.gov/ct2/show/NCT02665650?term=affimed&rank=2

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
Recruitment Status : Terminated (Non-favorable risk/benefit profile with studied dosing regimen)
First Posted : April 8, 2014
Last Update Posted : May 16, 2019

https://clinicaltrials.gov/ct2/show/NCT02106091?term=affimed&rank=3
This was already announced March 27th, 2019 =>

Sure - but the main intention for Affimed is to deal it to a partner who may do whatever they want with AFM11.
FYI the whole answer from the last $AFMD conference call https://t.co/DPdQjQwLQG pic.twitter.com/G09GPTjV7j

— `((,(Dieter 'Hovekamp)))🇺🇦👥🤝👥🇷🇺 ☮️🕊️ (@dhovekamp42) April 24, 2019